康臣药业2023 年度报告

Contents目錄 Corporate Information2-4Chairman’s Statement5-14Financial Highlights15Management Discussion and Analysis16-26Directors and Senior Management Profile27-36Corporate Governance Report37-61Report of Directors62-88Independent Auditor’s Report89-99Consolidated Statement of Profit or Loss100Consolidated Statement of Profit or Loss andOther Comprehensive Income101Consolidated Statement of Financial Position102-103Consolidated Statement of Changes in Equity104-105Consolidated Cash Flow Statement106Notes to the Consolidated Financial Statements107-235Five-Year Financial Summary236 公司資料Corporate Information DIRECTORS 董事 執行董事 Executive Directors 20241 1720241 17 Mr. An Meng(Chairman, and appointed as theChief Executive Officer on 17 January 2024)Ms. Li Qian(Vice Chairlady and Chief Executive Officer)(resigned, effective from 17 January 2024)Professor Zhu QuanMr. Xu Hanxing 非執行董事 Non-Executive Director Dr. Zhang Lihua 獨立非執行董事 Independent Non-Executive Directors Mr. Feng ZhongshiMs. Chen YujunMr. Su Yuanfu(resigned, effective from 25 March 2024) 20243 25 審核委員會 AUDIT COMMITTEE Ms. Chen Yujun(Committee Chairlady)Dr. Zhang Lihua(appointed on 25 March 2024)Mr. Feng ZhongshiMr. Su Yuanfu(resigned, effective from 25 March 2024) 20243 2520243 25 提名委員會 NOMINATION COMMITTEE 20243 2520243 25 Mr. Feng Zhongshi(Committee Chairman)(appointed on 25 March 2024)Mr. An MengMs. Chen YujunMr. Su Yuanfu(Committee Chairman)(resigned, effective from 25 March 2024) 薪酬委員會 REMUNERATION COMMITTEE 20243 2520243 25 Mr. Feng Zhongshi(Committee Chairman)Mr. An MengMs. Chen Yujun(appointed on 25 March 2024)Mr. Su Yuanfu(resigned, effective from 25 March 2024) 環境、社會及管治委員會 ENVIRONMENTAL, SOCIAL AND GOVERNANCECOMMITTEE Mr. An Meng(Committee Chairman)Mr. Feng ZhongshiMs. Chen Yujun 公司秘書 COMPANY SECRETARY Mr. Yau Chi Ming(CPA) AUTHORISED REPRESENTATIVES FOR THEPURPOSE OF THE LISTING RULES 就上市規則而言的授權代表 Mr. An MengMr. Yau Chi Ming 核數師 AUDITOR 108 KPMGPublic Interest Entity Auditor registered in accordance with theAccounting and Financial Reporting Council Ordinance8th Floor, Prince’s Building10 Chater Road, Central, Hong Kong LEGAL ADVISER (AS TO HONG KONG LAW) 法律顧問（香港法律） 1922 Li & Partners22nd FloorWorld-Wide House19 Des Voeux Road CentralHong Kong 註冊地址 REGISTERED ADDRESS Windward 3Regatta Office ParkPO Box 1350Grand Cayman KY1-1108Cayman Islands Windward 3Regatta Office ParkPO Box 1350Grand Cayman KY1-1108Cayman Islands HEADQUARTERS IN THE PRC 中國總部 71 71, Dongpeng AvenueEasternsection,Guangzhou Economic and TechnologicalDevelopment DistrictGuangzhou, PRC 香港主要營業地點 PRINCIPAL PLACE OF BUSINESS IN HONG KONG 22nd FloorWorld-Wide House19 Des Voeux Road CentralHong Kong 1922 公司資料Corporate Information 香港聯絡辦公室 LIAISON OFFICE IN HONG KONG 62803 Room 803Wing On Plaza62 Mody RoadTsimshatsui, Kowloon PRINCIPAL BANKERS 主要往來銀行 Bank of China (Hong Kong) LimitedBNP ParibasChina Construction BankChina Merchants BankDBS BankIndustrial and Commercial Bank of ChinaThe Hongkong and Shanghai Banking Corporation Limited 主要證券登記處 PRINCIPAL SHARE REGISTRAR Ocorian Trust (Cayman) LimitedWindward 3Regatta Office ParkPO Box 1350Grand Cayman KY1-1108Cayman Islands Ocorian Trust (Cayman) LimitedWindward 3Regatta Office ParkPO Box 1350Grand Cayman KY1-1108Cayman Islands HONG KONG BRANCH SHARE REGISTRAR 香港證券登記分處 183171712-1716 Computershare Hong Kong Investor Services LimitedShops 1712-1716, 17th Floor Hopewell Centre183 Queen’s Road EastWanchai, Hong Kong 公司網站 COMPANY WEBSITE www.chinaconsun.com www.chinaconsun.com 股份代號 STOCK CODE 1681 各位股東： Dear Shareholders, Onbehalf of the board(the“Board”of directors(the“Directors”of Consun Pharmaceutical Group Limited(the“Company”,I am pleased to present the auditedconsolidatedresults of the Company and its subsidiaries(collectivelyreferred as the“Group”,“Consun”,“ConsunPharmaceutical” or “Consun Pharmaceutical Group”for theyear ended 31 December 2023. 本公司董事董事局本集團康臣康臣葯業康臣葯業集團20231231 一、行業及業務回顧 I.Industrial and Business Review 202325202325.910.7%7.814.9% In 2023, with the global pandemic subsiding, variousindustries,including the pharmaceutical industry,gradually returned to normal, but difficulties and trialsremained. On the one hand, rising demand of peopleforhealth and medical care drove the consumptionupgradeof the pharmaceutical market.On the otherhand, the State continued to promote the normalizationofcentralized drug procurement,and accelerate therestructuring,transformation and upgrading of thepharmaceuticalindustry.Since the second half oftheyear,a compliance storm has swept across theindustry.A number of ministries and commissions ofthe State have jointly carried out a one-year medicalanti-corruption campaign with efforts of unprecedentedstrength,which has had a major impact on theindustry.Despite the many challenges faced by thepharmaceuticalindustry,Consun Pharmaceuticalisconfidently embarking on its“next 25 years”ofdevelopment.In the face of